TYRA Stock Analysis: Buy, Sell, or Hold?
TYRA - Tyra Biosciences, Inc. Common Stock
$31.88
-1.18 (-3.57%)
▼
5d:
+4.08%
30d:
+8.4%
90d:
-8.26%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
9d
Smart Money Accumulation
None View Scanner →
Strength: 3.1/10
Get Alerted When TYRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TYRA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TYRA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TYRA is currently trading at $31.88, which is considered fair relative to its 30-day fair value range of $30.67 to $32.51.
Technical Outlook: Technically, TYRA is in a strong downtrend. Immediate support is located at $29.70, while resistance sits at $33.26. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.97 (+63.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TYRA is in a strong downtrend. Immediate support is located at $29.70, while resistance sits at $33.26. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.97 (+63.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$30.67 -
$32.51
Company Quality Score
46/100
(HOLD)
Options IV Signal
47th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
69.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 47th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 63.0% below Wall St target ($51.97)
Trading Range Analysis
30-Day Trading Range
$30.67 -
$32.51
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$5.90
(18.5%)
Support & Resistance Levels
Support Level
$29.70
Resistance Level
$33.26
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.16
Wall Street Target
$51.97
(+63.0%)
Share & Embed Analysis
Last updated: August 02, 2026 10:34 PM ET
Data refreshes hourly during market hours. Next update: 11:34 PM
Data refreshes hourly during market hours. Next update: 11:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TYRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilla Kaplan
SELL
14295 shares
2026-03-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
